In the BioHarmony Drug Report Database
Everolimus
Afinitor, Afinitor Disperz, Zortress, Votubia (everolimus) is a small molecule pharmaceutical. Everolimus was first approved as Afinitor on 2009-03-30. It has been approved in Europe to treat breast neoplasms, pancreatic neoplasms, renal cell carcinoma, and tuberous sclerosis. The pharmaceutical is active against serine/threonine-protein kinase mTOR. In addition, it is known to target Cytochrome P450. Afinitor’s patents are valid until 2028-07-01 (FDA).
Trade Name
|
Afinitor, Votubia |
|---|---|
Common Name
|
everolimus |
ChEMBL ID
|
CHEMBL1908360 |
Indication
|
breast neoplasms, pancreatic neoplasms, renal cell carcinoma, tuberous sclerosis |
Drug Class
|
Immunosuppressives: immunosuppressant, rapamycin derivatives |
Image (chem structure or protein)